TY - JOUR
T1 - Myocardial fibrosis at cardiac MRI helps predict adverse clinical outcome in patients with mitral valve prolapse
AU - Figliozzi, Stefano
AU - Georgiopoulos, Georgios
AU - Lopes, Pedro M.
AU - Bauer, Klemens B.
AU - Moura-Ferreira, Sara
AU - Tondi, Lara
AU - Mushtaq, Saima
AU - Censi, Stefano
AU - Pavon, Anna Giulia
AU - Bassi, Ilaria
AU - Servato, Maria Luz
AU - Teske, Arco J.
AU - Biondi, Federico
AU - Filomena, Domenico
AU - Pica, Silvia
AU - Torlasco, Camilla
AU - Muraru, Denisa
AU - Monney, Pierre
AU - Quattrocchi, Giuseppina
AU - Maestrini, Viviana
AU - Agati, Luciano
AU - Monti, Lorenzo
AU - Pedrotti, Patrizia
AU - Vandenberk, Bert
AU - Squeri, Angelo
AU - Lombardi, Massimo
AU - Ferreira, António M.
AU - Schwitter, Juerg
AU - Aquaro, Giovanni Donato
AU - Chiribiri, Amedeo
AU - Rodríguez Palomares, José F.
AU - Yilmaz, Ali
AU - Andreini, Daniele
AU - Florian, Anca
AU - Leiner, Tim
AU - Abecasis, João
AU - Badano, Luigi Paolo
AU - Bogaert, Jan
AU - Masci, Pier Giorgio
N1 - Publisher Copyright:
© RSNA, 2022.
PY - 2023/1
Y1 - 2023/1
N2 - Background: Patients with mitral valve prolapse (MVP) may develop adverse outcomes even in the absence of mitral regurgitation or left ventricular (LV) dysfunction. Purpose: To investigate the prognostic value of mitral annulus disjunction (MAD) and myocardial fibrosis at late gadolinium enhancement (LGE) cardiac MRI in patients with MVP without moderate-to-severe mitral regurgitation or LV dysfunction. Materials and Methods: In this longitudinal retrospective study, 118 144 cardiac MRI studies were evaluated between October 2007 and June 2020 at 15 European tertiary medical centers. Follow-up was from the date of cardiac MRI examination to June 2020; the minimum and maximum follow-up intervals were 6 months and 156 months, respectively. Patients were excluded if at least one of the following conditions was present: cardiomyopathy, LV ejection fraction less than 40%, ischemic heart disease, congenital heart disease, inflammatory heart disease, moderate or worse mitral regurgitation, participation in competitive sport, or electrocardiogram suggestive of channelopathies. In the remainder, cardiac MRI studies were reanalyzed, and patients were included if they were aged 18 years or older, MVP was diagnosed at cardiac MRI, and clinical information and electrocardiogram monitoring were available within 3 months from cardiac MRI examination. The end point was a composite of adverse outcomes: sustained ventricular tachycardia (VT), sudden cardiac death (SCD), or unexplained syncope. Multivariable Cox regression analysis was performed. Results: A total of 474 patients (mean age, 47 years ± 16 [SD]; 244 women) were included. Over a median follow-up of 3.3 years, 18 patients (4%) reached the study end point. LGE presence (hazard ratio, 4.2 [95% CI: 1.5, 11.9]; P = .006) and extent (hazard ratio, 1.2 per 1% increase [95% CI: 1.1, 1.4]; P = .006), but not MAD presence (P = .89), were associated with clinical outcome. LGE presence had incremental prognostic value over MVP severity and sustained VT and aborted SCD at baseline (area under the receiver operating characteristic curve, 0.70 vs 0.62; P = .03). Conclusion: In contrast to mitral annulus disjunction, myocardial fibrosis determined according to late gadolinium enhancement at cardiac MRI was associated with adverse outcome in patients with mitral valve prolapse without moderate-to-severe mitral regurgitation or left ventricular dysfunction.
AB - Background: Patients with mitral valve prolapse (MVP) may develop adverse outcomes even in the absence of mitral regurgitation or left ventricular (LV) dysfunction. Purpose: To investigate the prognostic value of mitral annulus disjunction (MAD) and myocardial fibrosis at late gadolinium enhancement (LGE) cardiac MRI in patients with MVP without moderate-to-severe mitral regurgitation or LV dysfunction. Materials and Methods: In this longitudinal retrospective study, 118 144 cardiac MRI studies were evaluated between October 2007 and June 2020 at 15 European tertiary medical centers. Follow-up was from the date of cardiac MRI examination to June 2020; the minimum and maximum follow-up intervals were 6 months and 156 months, respectively. Patients were excluded if at least one of the following conditions was present: cardiomyopathy, LV ejection fraction less than 40%, ischemic heart disease, congenital heart disease, inflammatory heart disease, moderate or worse mitral regurgitation, participation in competitive sport, or electrocardiogram suggestive of channelopathies. In the remainder, cardiac MRI studies were reanalyzed, and patients were included if they were aged 18 years or older, MVP was diagnosed at cardiac MRI, and clinical information and electrocardiogram monitoring were available within 3 months from cardiac MRI examination. The end point was a composite of adverse outcomes: sustained ventricular tachycardia (VT), sudden cardiac death (SCD), or unexplained syncope. Multivariable Cox regression analysis was performed. Results: A total of 474 patients (mean age, 47 years ± 16 [SD]; 244 women) were included. Over a median follow-up of 3.3 years, 18 patients (4%) reached the study end point. LGE presence (hazard ratio, 4.2 [95% CI: 1.5, 11.9]; P = .006) and extent (hazard ratio, 1.2 per 1% increase [95% CI: 1.1, 1.4]; P = .006), but not MAD presence (P = .89), were associated with clinical outcome. LGE presence had incremental prognostic value over MVP severity and sustained VT and aborted SCD at baseline (area under the receiver operating characteristic curve, 0.70 vs 0.62; P = .03). Conclusion: In contrast to mitral annulus disjunction, myocardial fibrosis determined according to late gadolinium enhancement at cardiac MRI was associated with adverse outcome in patients with mitral valve prolapse without moderate-to-severe mitral regurgitation or left ventricular dysfunction.
UR - https://www.scopus.com/pages/publications/85160544787
U2 - 10.1148/radiol.220454
DO - 10.1148/radiol.220454
M3 - Article
C2 - 36098639
AN - SCOPUS:85160544787
SN - 0033-8419
VL - 306
SP - 112
EP - 121
JO - Radiology
JF - Radiology
IS - 1
ER -